These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 24509169)
21. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma. Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516 [TBL] [Abstract][Full Text] [Related]
22. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype. Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228 [TBL] [Abstract][Full Text] [Related]
24. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both? Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391 [TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Almasri NM; Al Hamad M Breast Cancer Res; 2005; 7(5):R598-604. PubMed ID: 16168103 [TBL] [Abstract][Full Text] [Related]
26. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083 [TBL] [Abstract][Full Text] [Related]
27. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases. Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I J BUON; 2012; 17(2):277-83. PubMed ID: 22740206 [TBL] [Abstract][Full Text] [Related]
28. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579 [TBL] [Abstract][Full Text] [Related]
29. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. Ayadi L; Khabir A; Amouri H; Karray S; Dammak A; Guermazi M; Boudawara T World J Surg Oncol; 2008 Oct; 6():112. PubMed ID: 18945339 [TBL] [Abstract][Full Text] [Related]
30. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers. Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923 [TBL] [Abstract][Full Text] [Related]
31. Is triple negative a prognostic factor in breast cancer? Nishimura R; Arima N Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692 [TBL] [Abstract][Full Text] [Related]
32. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer. Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205 [TBL] [Abstract][Full Text] [Related]
33. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. Lindström LS; Karlsson E; Wilking UM; Johansson U; Hartman J; Lidbrink EK; Hatschek T; Skoog L; Bergh J J Clin Oncol; 2012 Jul; 30(21):2601-8. PubMed ID: 22711854 [TBL] [Abstract][Full Text] [Related]
34. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis. Tas F Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972 [TBL] [Abstract][Full Text] [Related]
35. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer. Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894 [TBL] [Abstract][Full Text] [Related]
36. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Bolli M; Kocher T; Adamina M; Guller U; Dalquen P; Haas P; Mirlacher M; Gambazzi F; Harder F; Heberer M; Sauter G; Spagnoli GC Ann Surg; 2002 Dec; 236(6):785-93; discussion 793. PubMed ID: 12454517 [TBL] [Abstract][Full Text] [Related]
37. Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients. Puzovic V; Brcic I; Ranogajec I; Jakic-Razumovic J Neoplasma; 2014; 61(4):439-46. PubMed ID: 24645837 [TBL] [Abstract][Full Text] [Related]
38. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Tsutsumi Y Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930 [TBL] [Abstract][Full Text] [Related]
39. Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer. Xu Y; Wang C; Zhang Y; Jia L; Huang J Sci Rep; 2015 Jul; 5():12104. PubMed ID: 26175056 [TBL] [Abstract][Full Text] [Related]
40. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Taback B; Chan AD; Kuo CT; Bostick PJ; Wang HJ; Giuliano AE; Hoon DS Cancer Res; 2001 Dec; 61(24):8845-50. PubMed ID: 11751407 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]